Phenotypic profiling in pancreatic cancer: promise meets practical limits

Findings from the COMPASS trial, aimed at establishing "the feasibility of a comprehensive real-time genomic analysis of pancreatic ductal adenocarcinoma (PDAC) using whole genome sequencing and RNA sequencing".  While phenotypic profiling has been shown to be effective in treatment-based outcomes, a significant challenge is the 1.5-2 months of time required to receive whole genome sequencing results. 

Click here to learn more.